Get started
Author

Brenda Chimal‐Vega

Observed names: BRENDA CHIMAL VEGA, Brenda Chimal Vega, Brenda Chimal-Vega, Chimal-Vega Brenda
ORCID: 0000-0002-2238-0708
Observed ORCID: 0000-0002-2238-0708
OpenAlex ID: A5089211008
Recent Advances by In Silico and In Vitro Studies of Amyloid-β 1-42 Fibril Depicted a S-Shape Conformation
2018 · Daniel Miguel Ángel Villalobos Acosta, Brenda Chimal Vega, et al. · International Journal of Molecular Sciences · 25
PDF
LDL Promotes Disorders in β-Cell Cholesterol Metabolism, Implications on Insulin Cellular Communication Mediated by EVs
2022 · Lizbeth Guevara-Olaya, Brenda Chimal-Vega, et al. · Metabolites · 22
PDF
eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model
2022 · Alina González-Ortiz, Angel Pulido-Capiz, et al. · Cells · 21
PDF
Inter-Tissue Communication Mechanisms via Exosomes and Their Implications in Metabolic Diseases: Opportunities for Pharmacological Regulation
2025 · Brenda Chimal-Vega, Jesus Emanuel Maldonado-Arvizu, et al. · Future Pharmacology · 16
G-2548A Leptin Promoter and Q223R Leptin Receptor Polymorphisms in Obese Mexican Subjects
2013 · P. Carrillo-Vazquez Jonathan, Lopez-Alcantar Jeronimo, et al. · American Journal of Agricultural and Biological Sciences · 14
PDF
Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone
2025 · Jorge Hernández-Valencia, Ruth García-Villarreal, et al. · International Journal of Molecular Sciences · 7
PDF
Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model
2024 · Angel Pulido-Capiz, Brenda Chimal-Vega, et al. · Pharmaceutics · 6
PDF
Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance
2024 · Andrea Muñoz-Ayala, Brenda Chimal-Vega, et al. · Bioscience Reports · 6
PDF
Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance
2022 · Andrea Muñoz-Ayala, Brenda Chimal-Vega, et al. · Advances in protein chemistry and structural biology · 6
The transition from preclinical to clinical obesity: the importance of a borderline stage
2026 · Jesus E. Maldonado-Arvizu, Paula Vanessa Rios-Verdugo, et al. · Clinical Science · 4
Advances in the development of protein tyrosine phosphatase 1B inhibitor, evaluated by in vitro and in vivo assays
2025 · Victor G. García-González, Ana Brenda Ortega Morales, et al. · Results in Chemistry · 4
Potential Ligands to Resistin Against Prostate Cancer, Evaluated by Molecular Docking and In Vitro Assays to Develop an Anticancer Drug
2025 · Bryan A. Rivera‐Suárez, Victor G. García González, et al. · Chemistry & Biodiversity · 4
Exploring the structure and conformational landscape of human leptin. A molecular dynamics approach
2015 · Brenda Chimal-Vega, Norma Paniagua-Castro, et al. · Journal of Theoretical Biology · 3
Cryptotanshinone: an Encouraging Natural Compound for Treating Metabolic Diseases
2026 · Andrea Muñoz-Ayala, Jesús Emanuel Maldonado-Arvizu, et al. · Current Pharmacology Reports · 2
PDF
Low-Density Lipoproteins Increase Proliferation, Invasion, and Chemoresistance via an Exosome Autocrine Mechanism in MDA-MB-231 Chemoresistant Cells
2024 · César Y. Castañeda-Sánchez, Brenda Chimal-Vega, et al. · Biomedicines · 2
PDF
The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model
2026 · Héctor Frayde-Gómez, Brenda Chimal-Vega, et al. · Scientific Reports · 1
PDF
Potential Ligands to 3-Dehydroquinate Dehydratase (SaDHQD) of Staphylococcus aureus, Evaluated by Molecular Docking and In Vitro Assays to Develop an Antibiotic Drug
2026 · Julio Cesar Armenta-Gorosave, Gerson Ney Hernández-Acevedo, et al. · Scientia Pharmaceutica
Endoxifen Resistance in ER+ Breast Cancer Involves Translational Adaptation and Potential Contribution of ABCC Transporters
2026 · Gerson Ney Hernández-Acevedo, Angel Pulido-Capiz, et al. · Future Pharmacology
PDF
El Desarrollo de Fármacos contra la Diabetes Mellitus Tipo 2 utilizando otros Blancos Terapéuticos
2026 · Ana Brenda Ortega Morales, María José Oros Soto, et al. · Revista Veritas de Difusão Cientifica.
PDF
LDL-mediated chemoresistance to Lapatinib involves dysregulation of CYP3A4, SULT1A1, and HER2 signaling in HER2+ breast cancer
2025 · Victor Garcia-Gonzalez, Ruth Areli García-Villarreal, et al. · Research Square
PDF
Potential Otubain1 Inhibitor, an Approach for a Treatment against Breast Cancer.
2024 · Andrea Muñoz-Ayala, Victor G García-González, et al. · PubMed
PDF
Works count: 22
Citation count: 143
H-index: 6
I10-index: 5
Year
Topic
Type